Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diacerein 1% ointment open-label extension in epidermolysis bullosa simplex
NL-OMON48978Phase 2Completed
- Sponsor
- Medpace
- Start
- May 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of diacerein in epidermolysis bullosa simplex (EBS), sponsored by Medpace. Primary endpoint: Safety and tolerability. Started May 2018; status: completed.
02
Drugs
diacerein
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on NL-OMON48978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48978.